Skip to content

Safety and efficacy of maintenance of etomidate combined with sevoflurane in general anesthesia: a multi-center randomized controlled study

Safety and efficacy of maintenance of etomidate combined with sevoflurane in general anesthesia: a multi-center randomized controlled study

Status
Active, not recruiting
Phases
Early Phase 1
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2100049610
Enrollment
Unknown
Registered
2021-08-06
Start date
2021-08-31
Completion date
Unknown
Last updated
2022-04-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

Group 1:Etomidate and sevoflurane
Group 2:Propofol and sevoflurane

Sponsors

He'nan Provincial People's Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 65 Years

Inclusion criteria

Inclusion criteria: 1. Aged 18-65 years; 2. Type of surgery: laparoscopic gynecological surgery, laparoscopic gastrointestinal surgery, thoracoscopic radical resection of lung cancer; 3. 1 h <= operation time <= 3 h; 4. ASA classification I-III; 5. BMI is 18.5-29.9 kg/m^2 [BMI=weight (Kg)/height (m)^2] (2013 American ''Adult Overweight and Obesity Management Guidelines''); 6. In line with ethics, the patients were tested voluntarily and signed the informed consent.

Exclusion criteria

Exclusion criteria: 1. Cerebrovascular accident occurred within 3 months, such as stroke, transient ischemic attack (TIA), etc.; 2. Patients with severe abnormal liver and kidney function (severe liver function abnormality: one of ALT, AST, ALP, total bilirubin, etc. > 2 times the upper limit of the normal value. Severe renal dysfunction: creatinine > 2 times the upper limit of the normal value); 3. Patients with diabetic complications (diabetic ketoacidosis, hyperosmolar coma, various infections, macrovascular disease, diabetic nephropathy, retinopathy, diabetic cardiomyopathy, diabetic neuropathy, diabetic foot, etc.); 4. Those who have experienced unstable angina pectoris or myocardial infarction within 3 months; 5. Preoperative visit blood pressure >= 160/100 mmHg (2020 ISH Hypertension Guidelines >= grade 2 hypertension); 6. Confirmed/suspected of abuse or long-term use of narcotic sedative analgesics; 7. Those who have taken hormones or other immunosuppressive agents for >10 days within half a year, or have a history of adrenal cortex suppression or immune system diseases; 8. Those with hypothyroidism; 9. Those with a history of asthma; 10. Reoperation within 3 months; 11. Those who have contraindications or allergies to experimental drugs and other anesthetic drugs; 12. Patients enrolled in other studies within 30 days.

Design outcomes

Primary

MeasureTime frame
Rate of intraoperative hypertension and hypotension;Ricker sedation-agitation score after surgery;

Countries

China

Contacts

Public ContactZhang Jiaqiang

He'nan Provincial People's Hospital

hnmzxh@163.com+86 13937121360

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026